Search results for "Peptide receptor"

showing 4 items of 24 documents

Somatostatin and Somatostatin Receptors: From Signaling to Clinical Applications in Neuroendocrine Neoplasms

2021

Neuroendocrine neoplasms (NENs) are heterogeneous neoplasms which arise from neuroendocrine cells that are distributed widely throughout the body. Although heterogenous, many of them share their ability to overexpress somatostatin receptors (SSTR) on their cell surface. Due to this, SSTR and somatostatin have been a large subject of interest in the discovery of potential biomarkers and treatment options for the disease. The aim of this review is to describe the molecular characteristics of somatostatin and somatostatin receptors and its application in diagnosis and therapy on patients with NENs as well as the use in the near future of somatostatin antagonists.

endocrine systemQH301-705.5CellMedicine (miscellaneous)ReviewGeneral Biochemistry Genetics and Molecular BiologymedicineBiology (General)Tumorspeptide receptor radionuclide therapyReceptors d'hormonesneuroendocrine neoplasmssomatostatin analoguesSomatostatin receptorbusiness.industryTreatment optionsLU-DOTA-TATEmedicine.anatomical_structureSomatostatinPotential biomarkerssomatostatin receptorssomatostatin antagonistsCancer research68Ga PETbusinesshormones hormone substitutes and hormone antagonistsBiomedicines
researchProduct

Peptide Receptor Radionuclide Therapy for Neuroendocrine Neoplasms in Germany: a Multi-Institutional Registry Study with Prospective Follow Up on 450…

2013

68 Ga-DOTATOC PET in patients with neuroendocrine tumors (NET). We specifically looked for incremental lesions, defined as lesions only observed on one modality even after extensive retrospective evaluation of the other modality. Methods: Twenty patients with a metastasized NET underwent 111 In-pentetreotide

medicine.medical_specialtyPediatricsgenetic structuresPeptide receptorbusiness.industryRegistry studyHematologyNeuroendocrine tumorsmedicine.diseaseOncologyRadionuclide therapyotorhinolaryngologic diseasesmedicineIn patientRadiologyReceptorbusinesspsychological phenomena and processesAnnals of Oncology
researchProduct

Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death

2015

The immunogenicity of malignant cells has recently been acknowledged as a critical determinant of efficacy in cancer therapy. Thus, besides developing direct immunostimulatory regimens, including dendritic cell-based vaccines, checkpoint-blocking therapies, and adoptive T-cell transfer, researchers have started to focus on the overall immunobiology of neoplastic cells. It is now clear that cancer cells can succumb to some anticancer therapies by undergoing a peculiar form of cell death that is characterized by an increased immunogenic potential, owing to the emission of the so-called "damage-associated molecular patterns" (DAMPs). The emission of DAMPs and other immunostimulatory factors by…

medicine.medical_treatmentAPOPTOTIC CALRETICULIN EXPOSUREanti-tumor immunityimmunogenicityPHOTODYNAMIC THERAPY0302 clinical medicinetranslational medicineoncoimmunologyImmunology and AllergyCytotoxic T cellMedicineAnti-tumor immunity; Immunogenicity; Immunotherapy; Molecular medicine; Oncoimmunology; Patient prognosis; Translational medicine; Immunology; Immunology and Allergy0303 health sciencesanti-tumor immunity; immunogenicity; immunotherapy; molecular medicine; oncoimmunology; patient prognosis; translational medicineRIBOSOMAL-PROTEIN DIMERClassificationddc:3. Good health030220 oncology & carcinogenesisImmunogenic cell deathMolecular MedicineimmunotherapyACTIVATING POLYPEPTIDE-IIHIGH HYDROSTATIC-PRESSURElcsh:Immunologic diseases. AllergyANTICANCER IMMUNE-RESPONSESImmunology3122 Cancers610 Medicine & healthpatient prognosis03 medical and health sciencesImmune systemHUMAN TUMOR-CELLSFORMYL PEPTIDE RECEPTORS030304 developmental biologybusiness.industryTranslational medicineBiology and Life SciencesCYTOTOXIC T-LYMPHOCYTESImmunotherapyDendritic cellMolecular medicineNEGATIVE BREAST-CANCERImmunologyCancer cellmolecular dicine3111 Biomedicinebusinesslcsh:RC581-607Frontiers in Immunology
researchProduct

Extracellular matrix regulation of PTHrP and PTH/PTHrP receptor in a human breast cancer cell line

1999

AbstractIt was previously reported that 8701-BC breast cancer cells express the gene for parathyroid hormone-related peptide (PTHrP) and its cognate receptor (PTHrP-R), and release immunoreactive PTHrP in the extracellular medium; it was also found that PTHrP, in turn, exerts a role on the proliferative and invasive behavior in vitro of the same cell line. On the other hand, evidence has been produced that adhesion of 8701-BC cells onto different collagen substrates influences in various ways a number of phenotypic expressions, such as cell growth, motility, invasion of reconstituted basement membrane and production of lytic enzymes of the extracellular matrix (ECM). In light of these previ…

musculoskeletal diseasesmedicine.medical_specialtyParathyroid hormone-related peptideStromal cellRNA SplicingCellular differentiationBiophysicsBreast NeoplasmsBiologyPolymerase Chain ReactionBiochemistryExtracellular matrixBreast cancerStructural BiologyLamininInternal medicineGene expressionTumor Cells CulturedGeneticsmedicineExtracellularHumansParathyroid hormone-related peptide receptorMolecular BiologyReceptor Parathyroid Hormone Type 1Basement membraneParathyroid Hormone-Related ProteinProteinsCell DifferentiationCell Biologymusculoskeletal systemExtracellular MatrixNeoplasm ProteinsCell biologyGene Expression Regulation NeoplasticDrug CombinationsEndocrinologymedicine.anatomical_structureCell culturebiology.proteinReceptors Parathyroid HormoneProteoglycansGene expressionCollagenLamininhormones hormone substitutes and hormone antagonistsFEBS Letters
researchProduct